Pharmafile Logo

Impetus Digital: now offering carbon-neutral live meeting support

Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

- PMLiVE

A year after Impetus Digital first calculated and offset all of our home office-related emissions, we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have been–and will continue to be–offset. This means that–while we still encourage clients to go fully virtual to cut down on their meeting-associated emissions almost entirely–those opting for a hybrid event can still feel good knowing that any Impetus support staff attending the meeting in person is not contributing to the carbon footprint of the event.

In fact, we were recently promoted to the Aclymate Silver Tier for our efforts to date. Plus, we continue to be platinum-certified by the Green Business Benchmark (GBB), demonstrating our commitment to sustainable practices!

Impetus Digital has been certified as Silver tier Climate Wise by AclymateImpetus Digital is GBB platinum-certified

Phase 3 and beyond will involve calculating and offsetting the emissions associated with the actual meeting venues, any Impetus business trips for reasons other than attending live client meetings and events (e.g., conference attendance), and the small but non-negligible emissions associated with our online portals. Stay tuned for more updates!


  • Did you know that HCP advisors consider the minimal environmental impact as one of the top benefits of virtual small-group meetings such as advisory boards? (See other benefits here.)
  • To learn more best practices for sustainable meetings, make sure to check out our infographic on the topic.
  • Looking for other resources on how to plan and execute environmentally friendly life science meetings and events? We have lots! Send us an email and we’ll follow up with you directly.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Mastering Asynchronous Meetings: Open-Ended Questions – Impetus Digital Tip 1

Unlock the potential of asynchronous virtual meetings with the first tip from our "Top 10 Tips for Optimizing Asynchronous Virtual Meetings".

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Navigating Regulatory Challenges – Top 10 Most Important Advisor Questions

This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences...

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Engaging with Different Perspectives – Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...